- Advanced search
- Immuno Portal
- Malaria Portal
Ligand id: 5887
View more information in the IUPHAR Pharmacology Education Project: cabozantinib
Molecular properties generated using the CDK
|Compound class||Synthetic organic|
|Approved drug?||Yes (FDA (2012), EMA (2014))|
|International Nonproprietary Names|
|BMS907351 | Cabometyx® | Cometriq® | XL-184 | XL184|
|Cabozantinib is a Type-1, oral, small-molecule tyrosine kinase inhibitor.
Marketed formulations contain cabozantinib S-malate (PubChem CID 25102846).
|CAS Registry No.||849217-68-1 (source: SciFinder)|
|GtoPdb PubChem SID||178102511|
|Search Google for chemical match using the InChIKey||ONIQOQHATWINJY-UHFFFAOYSA-N|
|Search Google for chemicals with the same backbone||ONIQOQHATWINJY|
|Search PubMed clinical trials||cabozantinib|
|Search PubMed titles||cabozantinib|
|Search PubMed titles/abstracts||cabozantinib|
|Search UniChem for chemical match using the InChIKey||ONIQOQHATWINJY-UHFFFAOYSA-N|
|Search UniChem for chemicals with the same backbone||ONIQOQHATWINJY|
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.✖
Cat. No. 5422